S&P 500   4,442.99 (-0.28%)
DOW   34,919.98 (+0.35%)
QQQ   368.87 (-1.19%)
AAPL   144.58 (-1.59%)
MSFT   293.51 (-1.95%)
FB   351.17 (-0.51%)
GOOGL   2,822.25 (-0.78%)
TSLA   788.60 (+1.83%)
AMZN   3,366.72 (-1.72%)
NVDA   214.92 (-2.67%)
BABA   148.00 (+2.01%)
NIO   35.99 (+1.72%)
CGC   14.60 (+4.96%)
GE   105.95 (+2.07%)
MU   74.82 (+1.04%)
AMD   106.80 (+0.95%)
T   27.61 (+1.77%)
F   14.19 (+2.98%)
ACB   6.32 (+6.22%)
DIS   178.54 (+1.44%)
PFE   43.84 (-0.23%)
BA   226.20 (+2.17%)
BAC   43.19 (+2.49%)
S&P 500   4,442.99 (-0.28%)
DOW   34,919.98 (+0.35%)
QQQ   368.87 (-1.19%)
AAPL   144.58 (-1.59%)
MSFT   293.51 (-1.95%)
FB   351.17 (-0.51%)
GOOGL   2,822.25 (-0.78%)
TSLA   788.60 (+1.83%)
AMZN   3,366.72 (-1.72%)
NVDA   214.92 (-2.67%)
BABA   148.00 (+2.01%)
NIO   35.99 (+1.72%)
CGC   14.60 (+4.96%)
GE   105.95 (+2.07%)
MU   74.82 (+1.04%)
AMD   106.80 (+0.95%)
T   27.61 (+1.77%)
F   14.19 (+2.98%)
ACB   6.32 (+6.22%)
DIS   178.54 (+1.44%)
PFE   43.84 (-0.23%)
BA   226.20 (+2.17%)
BAC   43.19 (+2.49%)
S&P 500   4,442.99 (-0.28%)
DOW   34,919.98 (+0.35%)
QQQ   368.87 (-1.19%)
AAPL   144.58 (-1.59%)
MSFT   293.51 (-1.95%)
FB   351.17 (-0.51%)
GOOGL   2,822.25 (-0.78%)
TSLA   788.60 (+1.83%)
AMZN   3,366.72 (-1.72%)
NVDA   214.92 (-2.67%)
BABA   148.00 (+2.01%)
NIO   35.99 (+1.72%)
CGC   14.60 (+4.96%)
GE   105.95 (+2.07%)
MU   74.82 (+1.04%)
AMD   106.80 (+0.95%)
T   27.61 (+1.77%)
F   14.19 (+2.98%)
ACB   6.32 (+6.22%)
DIS   178.54 (+1.44%)
PFE   43.84 (-0.23%)
BA   226.20 (+2.17%)
BAC   43.19 (+2.49%)
S&P 500   4,442.99 (-0.28%)
DOW   34,919.98 (+0.35%)
QQQ   368.87 (-1.19%)
AAPL   144.58 (-1.59%)
MSFT   293.51 (-1.95%)
FB   351.17 (-0.51%)
GOOGL   2,822.25 (-0.78%)
TSLA   788.60 (+1.83%)
AMZN   3,366.72 (-1.72%)
NVDA   214.92 (-2.67%)
BABA   148.00 (+2.01%)
NIO   35.99 (+1.72%)
CGC   14.60 (+4.96%)
GE   105.95 (+2.07%)
MU   74.82 (+1.04%)
AMD   106.80 (+0.95%)
T   27.61 (+1.77%)
F   14.19 (+2.98%)
ACB   6.32 (+6.22%)
DIS   178.54 (+1.44%)
PFE   43.84 (-0.23%)
BA   226.20 (+2.17%)
BAC   43.19 (+2.49%)
NASDAQ:KRYS

Krystal Biotech Stock Forecast, Price & News

$57.55
+1.26 (+2.24 %)
(As of 09/27/2021 11:35 AM ET)
Add
Compare
Today's Range
$56.01
$58.09
50-Day Range
$52.01
$63.28
52-Week Range
$40.04
$87.29
Volume915 shs
Average Volume127,196 shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.11
30 days | 90 days | 365 days | Advanced Chart
Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.


Krystal Biotech logo

About Krystal Biotech

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.27 out of 5 stars

Medical Sector

282nd out of 1,352 stocks

Biological Products, Except Diagnostic Industry

37th out of 195 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Krystal Biotech?

Wall Street analysts have given Krystal Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Krystal Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Krystal Biotech
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its earnings results on Sunday, August, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.02.
View Krystal Biotech's earnings history
.

How has Krystal Biotech's stock price been impacted by Coronavirus?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KRYS shares have increased by 15.6% and is now trading at $57.72.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KRYS?

6 equities research analysts have issued 1 year target prices for Krystal Biotech's stock. Their forecasts range from $90.00 to $103.00. On average, they expect Krystal Biotech's share price to reach $97.50 in the next year. This suggests a possible upside of 68.9% from the stock's current price.
View analysts' price targets for Krystal Biotech
or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:
  • Krish S. Krishnan, Chairman, President & Chief Executive Officer
  • Suma M. Krishnan, Chief Operating Officer & Director
  • Trevor Parry, Director-IP & Scientific Affairs
  • Brittani Agostini, Manager-Clinical Operations
  • George Chen, Manager-Information Technology & CSV

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Redmile Group LLC (9.33%), FMR LLC (7.96%), BlackRock Inc. (6.90%), Lord Abbett & CO. LLC (5.37%), Vanguard Group Inc. (3.81%) and Frazier Management LLC (3.55%). Company insiders that own Krystal Biotech stock include Krish S Krishnan and Suma Krishnan.
View institutional ownership trends for Krystal Biotech
.

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Frazier Management LLC, Goldman Sachs Group Inc., Credit Suisse AG, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., Rafferty Asset Management LLC, Hood River Capital Management LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Krystal Biotech
or view top insider-selling stocks.

Which institutional investors are buying Krystal Biotech stock?

KRYS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Skandinaviska Enskilda Banken AB publ, Dimensional Fund Advisors LP, State Street Corp, BlackRock Inc., First Light Asset Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Krystal Biotech
or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $57.72.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $1.28 billion. The company earns $-32,170,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 75 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

Where are Krystal Biotech's headquarters?

Krystal Biotech is headquartered at 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at (412) 586-5830 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.